Sara McDonald
Gerontology · Sunnyside, WANPI 1639761133
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 37.8% of the total. Reporting peaked in 2021 at $645 and has fallen 64.4% since, to $230 in 2025.
Across 103 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$891
- Boehringer Ingelheim$230
- Bayer$183
- AbbVie$181
- Novo Nordisk$159
- Exact Sciences$74
- plus $636 from 17 others
What the payments were for
- Food & beverage$2,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $891 |
| Boehringer Ingelheim | 10 | $230 |
| Bayer | 8 | $183 |
| AbbVie | 9 | $181 |
| Novo Nordisk | 8 | $159 |
| Exact Sciences | 3 | $74 |
| Pfizer | 4 | $70 |
| Mylan Specialty L.p. | 3 | $64 |
| Johnson & Johnson | 3 | $64 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| GSK | 2 | $59 |
| Lundbeck LLC | 2 | $52 |
| Lilly USA, LLC | 2 | $40 |
| Novartis | 2 | $38 |
| Dexcom, Inc. | 1 | $29 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Myriad Genetic Laboratories, Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Viatris Specialty LLC | 1 | $22 |
| Merck | 1 | $17 |
| Alk-abello, Inc | 1 | $15 |
| BD | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$125
How this compares
$2,355 in reported general payments places this provider in the 85th percentile of 105 gerontology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 63 | $62,979 |
| JardianceEmpagliflozin | 34 | $55,891 |
| OzempicSemaglutide | 26 | $40,276 |
| RybelsusSemaglutide | 24 | $30,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $25,551 |
| TrulicityDulaglutide | 16 | $23,595 |
| EliquisApixaban | 17 | $19,309 |
| MyrbetriqMirabegron | 13 | $9,320 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $6,937 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,965 |
| Humulin NInsulin Nph Human Isophane | 18 | $2,765 |
| Atorvastatin Calcium | 130 | $1,868 |
| Losartan Potassium | 161 | $1,596 |
| Lisinopril | 140 | $1,497 |
| Tamsulosin Hcl | 76 | $1,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $159 | $70,78550 claims |
| AstraZenecaFarxiga | $891 | $62,97963 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $230 | $61,85646 claims |
| Lilly USA, LLCTrulicity, Humulin N | $40 | $26,36034 claims |
| GSKTrelegy Ellipta | $59 | $25,55126 claims |
| PfizerEliquis | $70 | $19,30917 claims |
| Sanofi-aventis U.S. LLCLantus | $60 | $1,30014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 gerontology providers in Washington.
Other gerontology in Sunnyside
- Amy WoodruffTacoma$118K
- Peter WilcoxSilverdale$16K
- Kristi ParrisSilverdale$10K
- Samuel GodinSilverdale$7K
- Byron TatschSpokane Valley$4K
- Catherine RehbergerTacoma$4K
- Nachole BrownSeattle$4K
- Si FengRichland$3K
- Shanti Benoit BoyceSeattle$3K
- Elizabeth MyrickSeattle$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.